3.74
Precedente Chiudi:
$3.88
Aprire:
$4
Volume 24 ore:
7.33M
Relative Volume:
1.88
Capitalizzazione di mercato:
$749.26M
Reddito:
$314.00K
Utile/perdita netta:
$-40.23M
Rapporto P/E:
-13.36
EPS:
-0.28
Flusso di cassa netto:
$-84.71M
1 W Prestazione:
+34.05%
1M Prestazione:
+77.25%
6M Prestazione:
+136.71%
1 anno Prestazione:
+147.68%
Atai Life Sciences N V Stock (ATAI) Company Profile
Nome
Atai Life Sciences N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
WALLSTRASSE 16, BERLIN
Confronta ATAI con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ATAI
Atai Life Sciences N V
|
3.74 | 748.87M | 314.00K | -40.23M | -84.71M | -0.28 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-18 | Reiterato | H.C. Wainwright | Buy |
2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
2022-11-01 | Iniziato | Loop Capital | Buy |
2021-11-30 | Iniziato | Maxim Group | Buy |
2021-11-11 | Iniziato | ROTH Capital | Buy |
2021-10-18 | Iniziato | H.C. Wainwright | Buy |
2021-09-01 | Iniziato | Jefferies | Buy |
2021-07-13 | Iniziato | Berenberg | Buy |
2021-07-13 | Iniziato | Canaccord Genuity | Buy |
2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
2021-07-13 | Iniziato | Citigroup | Buy |
2021-07-13 | Iniziato | Cowen | Outperform |
2021-07-13 | Iniziato | Credit Suisse | Outperform |
2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
What drives Atai Life Sciences N.V. stock priceExponential return rates - jammulinksnews.com
What analysts say about Atai Life Sciences N.V. stockMassive wealth growth - Autocar Professional
Is Atai Life Sciences N.V. a good long term investmentHigh-octane financial growth - jammulinksnews.com
5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Yahoo Finance
atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Atai Life Sciences N.V. Stock Analysis and ForecastFastest return on investment - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Why Atai Life Sciences N.V. stock attracts strong analyst attentionBreakout Momentum Stocks - beatles.ru
why atai life sciences n.v. stock attracts strong analyst attentionDaily Breakout Picks - Newser
How Atai Life Sciences N.V. stock performs during market volatilityMomentum Swing Watchlist - Newser
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target - Insider Monkey
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atai Life Sciences, Beckley Psytech Announce Positive Topline Results for BPL-003 - Yahoo.co
13 Best German Stocks to Invest in Now - Insider Monkey
Retail investors are Atai Life Sciences N.V.'s (NASDAQ:ATAI) biggest owners and were rewarded after market cap rose by US$121m last week - Yahoo Finance
atai Life Sciences stock rating reiterated at Buy by Aegis Capital - Investing.com Australia
atai Life Sciences stock maintains Buy rating after positive Phase 2b results - Investing.com
atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data - Investing.com Canada
Biotech Rips On Dual Announcement - The Globe and Mail
Atai Life Sciences’ Merger Sparks Market Buzz - timothysykes.com
Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up - Nasdaq
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewswire
Cathie Wood’s ARK ETF adjusts portfolio, buys Tesla and ATAI stock - Investing.com
Atai Life Sciences N.V. announced that it expects to receive $50 million in funding - MarketScreener
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? - Yahoo Finance
Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial - Bloomberg
Psychedelic advocates hopeful Trump administration will support space, STAT says - Yahoo Finance
Atai Life Sciences N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):